CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- 4 Open-market sale Senior VP, Chief Pharma Dev. sold 1,227 shares at an average $341.07 ($418,488)
- 4 Option exercise President and CEO acquired 50,000 shares (option exercise)
- 4 Open-market sale Director sold 15,470 shares at an average $347.45 ($5,375,126)
- 4 Open-market sale Director sold 20,000 shares at an average $356.44 ($7,128,759)
- 4 Open-market sale Chief Commercial Officer sold 347 shares at $335.24 ($116,328)
- 4 Open-market sale President and CEO sold 1,584 shares at $335.24 ($531,020)
- 4 Open-market sale Pres., R&D, and CMO sold 648 shares at $335.24 ($217,236)
- 4 Open-market sale Senior VP, Chief Pharma Dev. sold 103 shares at $335.24 ($34,530)
- 4 Open-market sale General Counsel sold 277 shares at $273.41 ($75,735)
- 4 Open-market sale Senior VP, Chief Pharma Dev. sold 442 shares at $273.41 ($120,847)
- 4 Open-market sale Pres., R&D, and CMO sold 1,689 shares at $273.41 ($461,789)
- 4 Open-market sale Director sold 3,600 shares at an average $315.31 ($1,135,122)
- 4 Open-market sale Director sold 3,400 shares at an average $350.30 ($1,191,028)
- 4 Open-market sale Chief Commercial Officer sold 688 shares at $316.92 ($218,041)
- 4 Planned sale Director sold 5,000 shares at $350.00 ($1,750,000)
- 4 Planned sale Director sold 5,000 shares at an average $300.94 ($1,504,703)
- 4 Gift Director gave 15,000 shares (gift)
- 4 Open-market sale President and CEO sold 6,363 shares at $243.83 ($1,551,490)
- 4 Grant or award General Counsel acquired 5,215 shares (grant or award)
- 3 Insider Initial Statement of Ownership
Page 5 of 29 · 564 filings